Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or...
Day: June 2, 2026
CVS Health Study Reveals a Need for Greater Digital Health Literacy for Medicare Members
Majority of respondents believe that low digital literacy is having a negative impact on their ability to manage their healthCVS...
HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
Bunkerhill Health’s FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through...
Bay Area Lyme Ventures Invests in Galaxy Diagnostics to Advance Tick-Borne Disease Testing
Partnership Aims to Accelerate Innovation in Diagnostic Tools for Patients with Complex Tick and Vector-Borne IllnessesDURHAM, NC., June 02, 2026...
ASHA: This Summer, Protect Your Hearing Without Missing the Fun
From Fireworks to Sports and Concerts, Simple Steps Can Help Protect Your HearingRockville, MD, June 02, 2026 (GLOBE NEWSWIRE) --...
Moderna to Present at Upcoming Conference in June 2026
CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following...
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
Appointments Add Deep Biopharmaceutical Commercial Strategy, Clinical and Finance Expertise as Company Advances Toward Potential Cytisinicline Approval and LaunchSEATTLE and...
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement...
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
-First ever IND submission for this disease, which has no current treatment or cure- -Quoin plans Phase 2 study initiation...
Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System
A leading academic center becomes the first user in the Southeast, Mid-Atlantic regionHINGHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) --...
TOMI Environmental Eyes Massive Expansion Opportunity as Food Industry Seeks Advanced Protection Against Emerging Pathogens
Massive Food Safety Market Opens for SteraMist® as Global Concern Over Ebola, Hantavirus, Norovirus and Other Emerging Pathogens Drives Demand...
INVO Fertility Announces Fiscal Year 2025 Financial Results
SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare...
Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission
Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerprinting Drug Screening System Company expects to complete enrollment...
Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout
Secured a new debt financing with funds and accounts managed by BlackRock and Claret Capital Partners, respectively for up to...
Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
Gedatolisib plus fulvestrant and palbociclib (the “gedatolisib-triplet”) reduced the risk of disease progression or death by 50% vs. alpelisib plus...
Hydrafacial Introduces HydraScalp® with Keravive™ as Next Evolution in Scalp Health
An advanced, non-invasive scalp treatment with no downtime, featuring newly engineered tips and clinically proven to visibly improve scalp health...
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing...
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually COMMACK, NY, June 02, 2026 (GLOBE NEWSWIRE)...
electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub
ROCKAWAY, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today...
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer’s Trial
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement...